Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for Prevention of Vasovagal Syncope
NCT02500732Phase 2Completed
- Sponsor
- University of Calgary
- Start
- Jul 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in vasovagal syncope comparing Atomoxetine Arm with Placebo Arm (2 arms). Primary endpoint: Number of Participants Who Become Syncopal Associated With Diagnostic Criteria of Hypotension and Bradycardia at 1 hour. Started Jul 2015; status: completed.
02
Drugs
atomoxetine
03
Conditions
vasovagal syncope
Beyond the preview
Go deeper on NCT02500732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02500732.